Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery

Annals of Thoracic Surgery

Volumn 77, Issue 2, 2004, Pages 711-713

  Cannon, Mark A ^a   Butterworth, John ^a   Riley, Robert D ^a   Hyland, Jacqueline M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; FENTANYL; HEPARIN; ISOFLURANE; MIDAZOLAM; PANCURONIUM; PIPECOLIC ACID DERIVATIVE;

AGED; ANAMNESIS; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; BLOOD; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; GRAFT OCCLUSION; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMODYNAMIC MONITORING; HUMAN; IMMUNOLOGY; MALE; MEDICAL DECISION MAKING; PAIN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REOPERATION; RESTENOSIS; STENT; THROMBOSIS; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS;

EID: 0442308025     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2003.04.001     Document Type: Article

References (8)

1. Trossaert M., Gaillard A., Commin P.L., Amiral J., Vissac A.M., Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol. 101:1998;653-655.
2. Pouplard C., May M.A., Iochmann S., et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin clinical implications for heparin-induced thrombocytopenia . Circulation. 99:1999;2530-2536.
3. Wilhelm M.J., Schmid C., Kececioglu D., Mollhoff T., Ostermann H., Scheld H.H. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg. 61:1996;920-924.
4. Kawada T., Kitagawa H., Hoson M., Okada Y., Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am. 14:2000;445-457.
5. D'Ancona G., Donias H.W., Karamanoukian R.L., Bergsland J., Karamanoukian H.L. OPCAB therapy survey off-pump clopidogrel, aspirin or both therapy survey . Heart Surg Forum. 4:2001;354-358.
6. Carrier M., Robitaille D., Perrault L.P., et al. Heparin versus danaparoid in off-pump coronary bypass grafting results of a prospective randomized clinical trial . J Thorac Cardiovasc Surg. 125:2003;325-329.
7. Walenga J.M., Fasanella A.R., Iqbal O., et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost. 25:(Suppl 1):1999;61-66.
8. Berry C.N., Girardot C., Lecoffre C., Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin comparison with heparin and recombinant Hirudin . Thromb Haemost. 72:1994;381-386.